Skip to content
DataLookout
Menu

TroFuse-055NCT07829783

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change.

  1. Notable Recruitment opened
    • Trial sites expanded: 0 → 10 locations
    • Start date changed from estimate of Oct 20, 2026 to Oct 23, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Event-Free Survival (EFS)
Timeframe: Up to approximately 60 months

Secondary (8)

Overall Survival (OS)
Distant Metastasis-Free Survival (DMFS)
Bladder Intact (BI)-EFS
Time to Occurrence of Non-Muscle-Invasive Bladder Cancer (NMIBC)
Disease-Specific Survival
Show 3 moreShow less
Rate of Radical Cystectomy
Number of Participants Who Experience One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Intervention Due to an AE

Arms and interventions

Sac-TMT + Pembrolizumab and Berahyaluronidase alfa + ChemoradiotherapyExperimental

Participants will receive sac-TMT 4 mg/kg by intravenous (IV) infusion every 2 weeks (q2w) for up to 6 doses plus pembrolizumab and berahyaluronidase alfa 790 mg SC every 6 weeks (q6w) for up to 2 doses. CRT (radiotherapy \[RT\] and concurrent chemotherapy) will then be administered to all participants as standard of care per treatment regimens chosen by the investigator. RT will include conventional radiation or hypofractionated radiation to the bladder for up to approximately 6.5 weeks. Concurrent chemotherapy will be administered with RT and will include cisplatin, or 5-fluorouracil (5-FU) + mitomycin C, or capecitabine + mitomycin C, or gemcitabine. Pembrolizumab and berahyaluronidase alfa 790 mg SC will be administered q6w for up to additional 7 cycles as consolidation therapy. Each cycle is 42 days (up to approximately 42 weeks).

ChemoradiotherapyExperimental

CRT (radiotherapy \[RT\] and concurrent chemotherapy) will then be administered to all participants as standard of care per treatment regimens chosen by the investigator. RT will include conventional radiation or hypofractionated radiation to the bladder for up to approximately 6.5 weeks. Concurrent chemotherapy will be administered with RT and will include cisplatin, or 5-fluorouracil (5-FU) + mitomycin C, or capecitabine + mitomycin C, or gemcitabine.

Biologicals: Sac-TMT, Pembrolizumab and Berahyaluronidase alfa

Drugs: Cisplatin, 5-FU, MMC, Capecitabine, Gemcitabine, Rescue Medications

Radiation: Conventional Radiotherapy, Hypofractionated radiotherapy

Sites

10 sites in 2 countries

Ukraine 9, Taiwan 1